Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 25,068 |
|
|||||
| News | - | ||||||
| Day High | 19.51 | Low High |
|||||
| Day Low | 18.58 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Q32 Bio Inc | QTTB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.07 | -5.44% | 18.61 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 19.15 | 18.58 | 19.51 | 18.61 | 19.68 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,176 | 25,068 | US$ 19.12 | US$ 479,180 | - | 15.07 - 32.88 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:08:44 | 10 | US$ 18.51 | USD |
Q32 Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 222.24M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Q32 Bio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/31/2024 | 15:25 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 5/09/2024 | 06:26 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 5/09/2024 | 06:18 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/09/2024 | 06:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/09/2024 | 05:59 | PR Newswire (US) | Q32 Bio Reports First Quarter 2024 Financial Results and.. |
| 4/03/2024 | 06:00 | PR Newswire (US) | Q32 Bio Appoints Lee Kalowski as President & Chief Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QTTB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.94 | 22.87 | 18.58 | 20.14 | 47,872 | -2.33 | -11.13% |
| 1 Month | 31.00 | 32.2135 | 18.58 | 25.06 | 53,179 | -12.39 | -39.97% |
| 3 Months | 16.24 | 32.88 | 15.07 | 25.27 | 45,397 | 2.37 | 14.59% |
| 6 Months | 16.24 | 32.88 | 15.07 | 25.27 | 45,397 | 2.37 | 14.59% |
| 1 Year | 16.24 | 32.88 | 15.07 | 25.27 | 45,397 | 2.37 | 14.59% |
| 3 Years | 16.24 | 32.88 | 15.07 | 25.27 | 45,397 | 2.37 | 14.59% |
| 5 Years | 16.24 | 32.88 | 15.07 | 25.27 | 45,397 | 2.37 | 14.59% |
Q32 Bio Description
| Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. |
